Document

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 6-K
 
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the month of October 2021
Commission File Number 001-40316
 
 
VECTIVBIO HOLDING AG
(Exact name of registrant as specified in its charter)
 
 

Aeschenvorstadt 36
4051 Basel
Switzerland
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 
 



VectivBio Holding AG is submitting this Report on Form 6-K to furnish its (i) unaudited interim condensed consolidated statement of financial position as of June 30, 2021 and (ii) unaudited interim condensed consolidated statement of income (loss) for the six months ended June 30, 2021, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Report on Form 6-K.


Exhibits  
 






SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  VECTIVBIO HOLDING AG
October 29, 2021
  

By:
 /s/ Claudia D'Augusta
   Claudia D’Augusta
   Chief Financial Officer


Document

VectivBio Holding AG
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
In thousands of USD






As of,

June 30, 2021

December 31, 2020

ASSETS





NON-CURRENT ASSETS





Property, plant and equipment    

115

173

Goodwill    

918

901

Intangible assets    

22,171

21,758

Right-of-use assets    

98

114

Financial assets    

61

64

Total non-current assets    

23,363

23,010

CURRENT ASSETS





Other current receivables    

523

963

Other current assets    

6,706

6,417

Cash and cash equivalents    

144,610

40,172

Total current assets    

151,839

47,552

Total assets    

175,202

70,562

EQUITY AND LIABILITIES





EQUITY





Net parent investment    

 

 

Share capital    

1,856

1,370

Reserves    

242,419

101,933

Accumulated losses    

 (103,873)

(71,065)

Total equity    

140,402

32,238

NON-CURRENT LIABILITIES





Lease liabilities    


4

Net pension liabilities    

2,997

3,557

Total non-current liabilities    

2,997

3,561

CURRENT LIABILITIES





Current liabilities related to business combinations    

20,000


Contingent consideration liabilities    


19,140

Trade payables    

3,062

9,490

Accrued expenses    

7,897

5,247

Other current liabilities    

745

774

Lease liabilities    

99

112

Total current liabilities    

31,803

34,763

Total liabilities        

34,800

38,324

Total equity and liabilities    

175,202

70,562


Document

VectivBio Holding AG
UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
In thousands of United States dollars ("USD")
Six Month Ended
June 30,
20212020
CONSOLIDATED STATEMENTS OF OPERATIONS
Research and development expenses(26,494)(10,660)
General and administrative expenses(19,097)(5,405)
Operating loss(45,591)(16,065)
Finance income15
Finance expense(23)(1,096)
Foreign exchange differences, net496(517)
Loss before income taxes(45,118)(17,677)
Income taxes
Net loss(45,118)(17,677)
Remeasurement of net pension liabilities508(511)
Total items that will not be reclassified subsequently to profit or loss508(670)
Exchange differences arising on translation of foreign operations(113)(670)
Total items that may be reclassified subsequently to profit or loss(113)(670)
Total other comprehensive loss, net of income tax395(1,181)
Total comprehensive loss(44,723)(18,858)
LOSS PER SHARE
Basic and diluted loss per share (in USD)(2.08)(1.85)